Drug Trial Radar · NCT05498428
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
520
Planned (sponsor's estimate)
Start
Nov 11, 2022
Primary completion
Aug 17, 2027
Study completion Aug 18, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Conditions
- Carcinoma, Non-small-Cell Lung
Interventions
AmivantamabDrug
Amivantamab will be administered subcutaneously by manual injection.
LazertinibDrug
Lazertinib will be administered as an oral tablet.
CarboplatinDrug
Carboplatin will be administrated by IV infusion.
PemetrexedDrug
Pemetrexed will be administered by IV infusion.
Direct Oral Anticoagulant (DOAC)Drug
DOAC will be administered orally.
Low Molecular Weight Heparin (LMWH)Drug
LMWH will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All Cohorts Except Cohort 4: Objective Response Rate (ORR) Based on Investigator Assessment (INV)Time frame: Up to 1 year 6 months
- Cohort 4: Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 4 years and 9 months
- Cohort 4: Number of Participants with AEs by SeverityTime frame: Up to approximately 4 years and 9 months
- Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory ValuesTime frame: Up to approximately 4 years and 9 months
- Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by SeverityTime frame: Up to approximately 4 years and 9 months
Locations
110 sites in 12 countries. Site status is shown where the registry gives one.
University of California at San Diego
La Jolla, California · Recruiting
University of California Irvine
Orange, California · Recruiting
Stanford Cancer Institute
Stanford, California · Recruiting
Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
Baptist Lynn Cancer Institute
Boca Raton, Florida · Completed
Mount Sinai Medical Center
Miami Beach, Florida · Recruiting
AdventHealth
Orlando, Florida · Recruiting
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida · Completed
University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Sidney Kimmel Cancer Center - Bayview Campus
Baltimore, Maryland · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Washington University School Of Medicine
St Louis, Missouri · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Hematology-Oncology Associates of CNY
East Syracuse, New York · Completed
Novant Health 1
Charlotte, North Carolina · Completed
Novant Health
Winston-Salem, North Carolina · Completed
Cleveland Clinic 1
Cleveland, Ohio · Completed
Cleveland Clinic
Cleveland, Ohio · Completed
Cleveland Clinic 2
Mayfield Heights, Ohio · Completed
Cleveland Clinic 3
Warrensville Heights, Ohio · Completed
The Huntsman Cancer Institute
Salt Lake City, Utah · Completed
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Providence Regional Cancer Partnership
Everett, Washington · Completed
Virginia Mason Medical Center
Seattle, Washington · Completed
Swedish Cancer Institute
Seattle, Washington · Recruiting
Fundacao Pio XII
Barretos, Brazil · Recruiting
PERSONAL Oncologia de Precisao e Personalizada
Belo Horizonte, Brazil · Recruiting
Hospital do Cancer de Londrina
Londrina, Brazil · Recruiting
Hospital Moinhos de Vento
Porto Alegre, Brazil · Recruiting
IDOR - Regional Rio de Janeiro
Rio de Janeiro, Brazil · Recruiting
IDOR - Regional Bahia
Salvador, Brazil · Recruiting
Hospital Alemao Oswaldo Cruz
São Paulo, Brazil · Recruiting
Impar Servicos Hospitalares SA Hospital Nove de Julho
São Paulo, Brazil · Completed
Fundacao Antonio Prudente A C Camargo Cancer Center
São Paulo, Brazil · Recruiting
Affiliated Hospital of Hebei University
Baoding, China · Completed
Jilin cancer hospital
Changchun, China · Recruiting
Sichuan Cancer Hospital
Chengdu, China · Recruiting
West China Hospital Sichuan University
Chengdu, China · Recruiting
The First Affiliated Hospital of PLA Army Medical University
Chongqing, China · Recruiting
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.